The role of senescence in cancer therapy-associated cardiovascular toxicity
Yasmin K. Alshoubaki , Vivienne Grüterich , Valentina Zollet , Gabriela M. Kuster
The Journal of Cardiovascular Aging ›› 2024, Vol. 4 ›› Issue (4) : 23
Cardiovascular diseases (CVDs) and cancer are the two leading causes of global mortality. Cancer treatments, including radiotherapy and chemotherapy, can have severe cardiotoxic side effects, raising concerns for cancer patients and increasing the financial burden on healthcare systems. Recent studies have shown a link between cancer therapy-induced cardiotoxicity and cardiac senescence. Specifically, systemic cancer therapies are known to induce cardiac senescence, which may directly result in cardiac dysfunction or enhance the vulnerability of the heart to other stressors. Besides anthracyclines, newer, more targeted therapies such as tyrosine kinase inhibitors (TKIs) have also been shown to induce cardiac senescence. Cellular senescence is triggered by DNA damage, oncogene activation, reactive oxygen and nitrogen species, and other stressors, leading to the secretion of proinflammatory factors, increased oxidative stress, and disruption of normal cellular functions. Understanding the molecular mechanisms of cardiac senescence induced by cancer therapy is essential for attenuating or even preventing clinically overt cardiotoxicity using senotherapies such as senolytics and senomorphics. In this review, cancer therapies that are associated with CVDs are described with an emphasis on the potential role of cardiac senescence in the disease progression. In addition, the known mechanisms by which anthracyclines, particularly doxorubicin (DOX), radiotherapy, and TKIs lead to cardiac senescence are highlighted. Finally, recent and novel senotherapies for treating cellular senescence are discussed with a focus on targeting cardiac senescence following cancer treatment. The field remains in its early stages, with further research required to clarify how cancer treatments contribute to cardiotoxicity. At the same time, identifying senotherapies that can be safely combined with cancer drugs is essential for targeting cardiac senescence and protecting cardiac health in cancer patients.
Cardiovascular senescence / cardiovascular diseases / cardiac senescence / cardiotoxicity / senotherapy / senolytics / senomorphics
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
de Lange T. How telomeres solve the end-protection problem.Science2009;326:948-52 PMCID:PMC2819049 |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
Di Micco R, Krizhanovsky V, Baker D, d'Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities.Nat Rev Mol Cell Biol2021;22:75-95 PMCID:PMC8344376 |
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
von Zglinicki T, Wan T, Miwa S. Senescence in post-mitotic cells: a driver of aging?.Antioxid Redox Signal2021;34:308-23 PMCID:PMC7821432 |
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
|
| [140] |
d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response.Nat Rev Cancer2008;8:512-22 |
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
|
| [147] |
|
| [148] |
|
| [149] |
|
| [150] |
|
| [151] |
|
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
|
| [157] |
|
| [158] |
|
| [159] |
|
| [160] |
|
| [161] |
|
| [162] |
|
| [163] |
|
| [164] |
|
| [165] |
|
| [166] |
|
| [167] |
|
| [168] |
|
| [169] |
|
| [170] |
|
| [171] |
|
| [172] |
|
| [173] |
|
| [174] |
|
| [175] |
|
| [176] |
|
| [177] |
|
| [178] |
|
| [179] |
|
| [180] |
|
| [181] |
|
| [182] |
|
| [183] |
|
| [184] |
|
| [185] |
|
| [186] |
|
| [187] |
|
| [188] |
|
| [189] |
|
| [190] |
|
| [191] |
|
| [192] |
|
| [193] |
|
| [194] |
|
| [195] |
|
| [196] |
|
| [197] |
|
| [198] |
|
| [199] |
|
| [200] |
|
| [201] |
|
| [202] |
|
| [203] |
AbbVie. A phase 2 open-label study evaluating tolerability and efficacy of navitoclax alone or in combination with Ruxolitinib in subjects with myelofibrosis (REFINE). 2017. Available from: https://clinicaltrials.gov/study/NCT03222609 [Last accessed on 14 Nov 2024] |
| [204] |
|
| [205] |
|
| [206] |
|
| [207] |
|
| [208] |
Wake Forest University Health Sciences. Phase II clinical trial to evaluate the safety and feasibility of senolytic therapy in Alzheimer’s disease. 2020. Available from: https://clinicaltrials.gov/study/NCT04685590 [Last accessed on 14 Nov 2024] |
| [209] |
|
| [210] |
|
| [211] |
|
| [212] |
Jonsson Comprehensive Cancer Center. A phase II randomized placebo-controlled study of fisetin and exercise to prevent frailty in breast cancer survivors. 2023. Available from: https://clinicaltrials.gov/study/NCT06113016 [Last accessed on 14 Nov 2024] |
| [213] |
Jonsson Comprehensive Cancer Center. A phase II randomized double-blind placebo-controlled study of fisetin to improve physical function in breast cancer survivors. 2022. Available from: https://clinicaltrials.gov/study/NCT05595499 [Last accessed on 14 Nov 2024] |
| [214] |
|
| [215] |
|
| [216] |
|
| [217] |
|
| [218] |
Albert Einstein College of Medicine. Metformin in Longevity Study (MILES). 2015. Available from: https://clinicaltrials.gov/study/NCT02432287 [Last accessed on 14 Nov 2024] |
| [219] |
University of Utah. Metformin to prevent inactivity-induced loss of muscle health during aging. 2017. Available from: https://clinicaltrials.gov/study/NCT03107884 [Last accessed on 14 Nov 2024] |
| [220] |
University of New Mexico. A double-blind, placebo-controlled trial of anti-aging, pro-autophagy effects of metformin in adults with prediabetes. 2017. Available from: https://clinicaltrials.gov/study/NCT03309007 [Last accessed on 14 Nov 2024] |
| [221] |
|
| [222] |
|
| [223] |
|
| [224] |
|
| [225] |
|
| [226] |
|
| [227] |
|
| [228] |
|
| [229] |
|
| [230] |
|
| [231] |
|
| [232] |
|
| [233] |
|
| [234] |
|
| [235] |
|
| [236] |
|
| [237] |
|
| [238] |
|
| [239] |
|
| [240] |
|
| [241] |
|
| [242] |
|
| [243] |
|
| [244] |
|
| [245] |
|
| [246] |
|
| [247] |
|
/
| 〈 |
|
〉 |